Comparison of Target- and IgG-Enrichment Strategies to Measure Adalimumab Concentrations in Human Plasma Using an Immunocapture-Liquid Chromatography-High-Resolution Mass Spectrometry Platform

참고문헌 (9)

1. Papamichael K, "Therapeutic drug monitoring of biologics in inflammatory bowel disease : unmet needs and future perspectives", Lancet Gastroenterol Hepatol, 7, pp.171~185 (2022)
2. EI Amrani M, "Six-step workflow for the quantification of therapeutic monoclonal antibodies in biological matrices with liquid chromatography mass spectrometry-a tutorial", Anal Chim Acta, 1080, pp.22~34 (2019)
3. Bartelds GM, "Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up", JAMA, 305, pp.1460~1468 (2011)
4. Ding X, "Early adalimumab and antiadalimumab antibody levels for prediction of primary nonresponse in ankylosing spondylitis patients", Clin Transl Sci, 13, pp.547~554 (2020)
5. Jordan G, "Evaluation of the potential use of hybrid LC-MS", MS for active drug quantification applying the ‘free analyte QC concept’, 2017, pp.9, 1705~1717
6. Iwamoto N, "Antibody drug quantitation in coexistence with anti-drug antibodies on nSMOL bioanalysis", Anal Biochem, 540-1, pp.30~37 (2018)
7. Tron C, "Quantification of infliximab and adalimumab in human plasma by a liquid chromatography tandem mass spectrometry kit and comparison with two ELISA methods", Bioanalysis, 14, pp.831~844 (2022)
8. Jenkins R, "Recommendations for validation of LC-MS", MS bioanalytical methods for protein biotherapeutics, 2015, pp.17, 1~16
9. Willeman T, "A multiplex liquid chromatography tandem mass spectrometry method for the quantification of seven therapeutic monoclonal antibodies : application for adalimumab therapeutic drug monitoring in patients with Crohn’s disease", Anal Chim Acta, 1067, pp.63~70 (2019)

관련 논문AI추천